The IV Conference on Minority Diseases of Bellvitge vindicates the key role of genetic reanalysis
Genetic studies that initially gave uncertain results can provide a reliable diagnosis if reviewed after two years
Absolute success of the Sinergia 2023 open day
This Saturday took place the open day of the fifth edition of Sinergia, the celebration of health research and innovation in L’Hospitalet. More than 300 people came to the Bellvitge Campus to take part in the everyday work of that IDIBELL, the Catalan Institute of Oncology, the Bellvitge University Hospital, the University of Barcelona and the Hospital Sant Joan de Déu do to improve people’s health.
Absolute success of the Sinergia 2023 open day Read More »
The Mediterranean diet and olive oil may benefit the prevention of some types of cancers related to obesity
A new study carried out by the Nutrition and Cancer research group of IDIBELL and the Catalan Institute of Oncology, with the collaboration of the scientific and technological center AZTI, offers a relevant review and update of data that demonstrates how eating habits and the microbiota intestine could play a key role in cancer prevention.
A new treatment to prevent infections acquired in the Intensive Care Unit (ICU) discovered by researchers from IDIBELL and the Bellvitge University Hospital enters the Clinical Phase
The new treatment is a drug that eliminates the antibodies that bind to gram-negative bacteria and makes them resistant to destruction by the immune system.
Sinergia will open its doors to Bellvitge health research and innovation
On the morning of Saturday, October 21, the 5th edition of Sinergia will bring the science of the Bellvitge Campus closer to citizens.
Sinergia will open its doors to Bellvitge health research and innovation Read More »
Researchers at CNIO and IDIBELL shed light on the role in lactation of a protein also crucial in breast cancer
When the RANK protein was suppressed in luminal cells of the breast tissue in female mice, they did not produce milk in their first pregnancy.
The IDIBELL’s spin-off ADmit therapeutics closes a €5.4 million funding round
ADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commercialization of a new early detection technology for Alzheimer’s disease (AD) and has successfully closed a €5.4 million equity round.
The IDIBELL’s spin-off ADmit therapeutics closes a €5.4 million funding round Read More »
Research led in Bellvitge will allow progress in the fight against bacteremia
The study has been published in the journal Nature Medicine, one of the most prestigious in Medicine, and represents a step forward to address an important health challenge worldwide, with high rates of therapeutic failure and mortality.
Research led in Bellvitge will allow progress in the fight against bacteremia Read More »
Sleep deprivation or working night shifts do not seem to be risk factors for endometrial cancer
A study by IDIBELL and ICO in 7,202 women with endometrial cancer and more than 22,000 control women found no relationship between lack of sleep or working night shifts with the development of this cancer.
Molecular tests allow more effective detection of endometrial cancer and avoid unnecessary hysterectomies in women with postmenopausal bleeding
The study performs an evaluation to determine the cost-effectiveness and profitability of two strategies for the early detection of endometrial cancer in women with postmenopausal bleeding.